Research programme: anti-CD160 monoclonal antibodies - Tolerx
Alternative Names: Autoimmune disorder therapeutics - TolerxLatest Information Update: 26 Feb 2008
At a glance
- Originator Tolerx
- Class Monoclonal antibodies
- Mechanism of Action Cytotoxic T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 26 Feb 2008 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral)
- 01 Sep 2005 Preclinical trials in Autoimmune disorders in USA (Parenteral)